A new treatment to prevent gonorrhea using bispecific antibodies applied topically.
Bispecific antibody for topical administration to prevent gonorrhea
This study is exploring a new way to help prevent gonorrhea using a special cream that boosts your body's defenses against the bacteria that cause the infection, offering a potentially safer and more effective option for those at risk.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Planet Biotechnology, INC. NIH-funded |
| Lab location | 1 site (Hayward, United States) |
| Project ID | NIH-11013480 on NIH RePORTER |
What this research studies
This research investigates a novel approach to prevent gonorrhea by developing a bispecific antibody that can be applied topically. The focus is on targeting the bacteria Neisseria gonorrhoeae, which has become resistant to many antibiotics. The methodology involves creating a fusion protein that enhances the immune response against the bacteria, aiming to reduce infection rates and associated complications. Patients may benefit from a new preventive measure that could be safer and more effective than current options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of gonorrhea infection, particularly sexually active individuals and those with multiple partners.
Not a fit: Patients who are already infected with gonorrhea or those who have no risk factors for the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new preventive treatment for gonorrhea, potentially reducing infection rates and associated health complications.
How similar studies have performed: While the approach of using bispecific antibodies is innovative, similar strategies in targeting bacterial infections have shown promise in preliminary studies.
Where this research is happening
Hayward, United States
- Planet Biotechnology, INC. — Hayward, United States (Active)
Researchers
- Principal investigator: Wycoff, Keith — Planet Biotechnology, INC.
- Study coordinator: Wycoff, Keith
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.